Inflammation and Depression: What Does the Immune System Really Have to Do With Mood?
- Sophroneo Psychiatry
- Jul 9
- 12 min read
The link between inflammation and depression is real enough to be a major area of psychiatric research, but it is often overstated online.
Researchers have repeatedly found that some inflammatory markers are higher, on average, in people with depression than in comparison groups. That does not mean every person with depression has excessive inflammation. It also does not prove that inflammation is the single cause of depression.
A large meta-analysis of inflammatory markers in depression found evidence of higher levels of several inflammatory markers, including C-reactive protein, or CRP, in people with major depressive disorder. The findings support an association between depression and altered immune activity, while also showing that inflammatory patterns vary between patients.he most important part of the story.
The future of inflammation research in psychiatry may not be about declaring that “depression is an inflammatory disease.” It may be about identifying whether a subgroup of patients has immune-related biology that affects symptoms or treatment response.
Is there really a link between inflammation and depression?
Yes. Research consistently supports an association between depression and inflammatory activity, although the strength and meaning of that association differ between individuals.
Inflammation is part of the immune system's response to threats, injury, infection, and other biological stressors.
Short-term inflammation can be protective.
Persistent or dysregulated inflammatory signaling may affect tissues and biological systems in more complicated ways.
Researchers studying major depressive disorder have examined inflammatory markers such as:
C-reactive protein, or CRP
Interleukin-6, or IL-6
Tumor necrosis factor alpha, or TNF-alpha
Interleukin-1 family signaling
Other cytokines and immune-related proteins
Cytokines are signaling proteins that help immune cells communicate.
Studies comparing people with and without depression have found average differences in some of these markers. Earlier meta-analytic research, for example, reported higher IL-6 and TNF-alpha concentrations among depressed participants.average*.
A research finding at the group level does not tell a clinician exactly what is happening in one patient's immune system.
Does inflammation cause depression?
Inflammation may contribute to depression in some situations, but the evidence does not support saying that inflammation causes every case of depression.
The relationship may move in several directions.
Possible relationship | Plain-language explanation |
Inflammation influences mood | Immune signaling may affect brain systems involved in motivation, energy, and reward |
Depression influences inflammation | Sleep disruption, chronic stress, reduced activity, or other depression-related factors may affect inflammatory biology |
A third factor affects both | Obesity, chronic illness, infection, trauma, or another factor may influence both mood and inflammation |
The relationship becomes cyclical | Depression-related changes and inflammatory signaling may reinforce each other |
Inflammation matters more in a subgroup | Some patients may have a more inflammatory biological profile than others |
Research involving immune-activating treatments has helped scientists take the first possibility seriously. Some patients receiving interferon-alpha in older medical treatment settings developed depressive symptoms during immune activation.
That provides evidence that immune signaling can influence mood and behavior.
It still does not mean a high cytokine level explains every person's depression.
Patients researching depression should be cautious with phrases such as:
“Your depression is caused by inflammation.”
“Your immune system is attacking your brain.”
“SSRIs cannot work if your CRP is high.”
“You need an anti-inflammatory instead of an antidepressant.”
Those statements move beyond what current research can establish for an individual patient.
What are cytokines, CRP, and neuroinflammation?
Cytokines are immune signaling proteins, CRP is a blood marker associated with systemic inflammation, and neuroinflammation refers broadly to immune-related activity involving the brain or central nervous system.
These terms are related, but they are not interchangeable.
Term | What it means |
Cytokine | A signaling protein involved in immune communication |
CRP | A protein produced mainly by the liver that rises with inflammatory signaling |
hs-CRP | A high-sensitivity CRP test that detects lower CRP concentrations |
Systemic inflammation | Inflammatory activity affecting the body more broadly |
Neuroinflammation | Immune-related activity involving the central nervous system |
Microglia | Immune-related cells that help maintain and respond to changes in the brain |
A blood CRP result does not directly measure inflammation inside the brain.
Similarly, finding increased inflammatory markers in a research population does not prove that microglia are excessively activated in every person with depression.
This distinction matters because the phrase neuroinflammation and depression is sometimes used online as though a standard blood test can show that someone's brain is inflamed.
That is not an accurate interpretation.
How might immune signals affect the brain?
Immune signaling may affect brain pathways involved in motivation, reward, energy, movement, and neurotransmitter function, but researchers are still studying the exact pathways and their importance in different patients.
Proposed mechanisms include changes involving:
Dopamine-related reward processing
Glutamate signaling
Tryptophan and kynurenine metabolism
Stress-response systems
Blood-brain barrier function
Microglial activity
Neural plasticity
One area of research involves the kynurenine pathway.
Tryptophan is an amino acid involved in several biological processes, including serotonin-related pathways. During immune activation, enzymes involved in tryptophan and kynurenine metabolism may become more active.
Researchers are studying whether changes in this pathway contribute to depression-related symptoms in some people.
The biology is more complicated than:
Inflammation uses up serotonin, so antidepressants stop working.
That explanation is too simple.
Researchers are instead examining networks of immune, metabolic, and nervous-system signals.
This helps explain why modern depression research is moving away from one-neurotransmitter stories.
Is there an inflammatory subtype of depression?
Researchers increasingly discuss the possibility of a more inflammatory depression profile, but “inflammatory depression” is not a simple diagnosis that can currently be confirmed with one blood test.
The hypothesis is that some people with depression may show:
Higher inflammatory biomarkers
Greater fatigue
Reduced motivation
Loss of pleasure
Psychomotor slowing
Metabolic health concerns
Different patterns of treatment response
These features are being studied.
However, symptoms such as fatigue and loss of pleasure are common in depression for many reasons.
A person should not assume:
“I am exhausted, so I have inflammatory depression.”
Similarly, a high CRP level can occur because of many medical factors.
The more careful research question is:
Can biomarkers help identify biologically meaningful subgroups of depression that respond differently to treatment?
That question is not fully answered yet.
What does CRP research tell us about antidepressant response?
CRP research suggests inflammation may help predict different patterns of antidepressant response, but CRP is not currently a stand-alone test that tells clinicians which depression medication will work.
A 2014 study examined CRP and treatment response among 241 people with depression who received escitalopram or nortriptyline. The CRP antidepressant-response study found that baseline CRP differentially predicted outcomes between the two medications.ed that CRP might eventually help guide medication selection.
That is scientifically interesting.
It is not the same as saying:
Low CRP means take an SSRI.
High CRP means avoid SSRIs.
A CRP result can diagnose treatment-resistant depression.
Every psychiatrist should use CRP to prescribe medication today.
Those conclusions would be stronger than the study supports.
The finding needs to be understood as part of biomarker-guided psychiatry research.
A biomarker is a measurable biological characteristic that may provide information about a condition or treatment response.
Psychiatry has long searched for reliable biomarkers that can guide individual treatment selection. CRP is attractive partly because it is already widely measured in general medicine.
Whether it can become part of a validated routine depression treatment algorithm remains an active research question.
Do not change medication without guidance from your prescriber.
Is inflammation linked to treatment-resistant depression?
Inflammation may be especially relevant to research on treatment-resistant depression, but it does not explain every case of treatment resistance.
Treatment-resistant depression, often shortened to TRD, generally refers to depression that has not improved enough after multiple appropriate treatment attempts.
A person may have difficult-to-treat depression for many possible reasons.
Examples include:
The original diagnosis needs reassessment
Previous treatments were not tolerated
Medication trials were incomplete
Bipolar symptoms are part of the clinical picture
Trauma or PTSD is significant
Severe insomnia is continuing
Substance use is affecting symptoms
A medical condition contributes to fatigue or mood changes
The person's depression genuinely has not responded to appropriate treatment
Inflammatory biology is one research area within that larger picture.
For patients whose depression has not improved enough, a treatment-resistant depression and depression care review may help organize treatment history and next-step questions.
The clinical goal should be broader than ordering an inflammation panel.
It should be to understand the full treatment history.
Are biologics being tested for depression?
Researchers have studied immune-targeting medications in depression, but biologics are not established routine treatments for major depressive disorder.
A biologic is a medicine produced using biological systems and often designed to target a specific protein or immune pathway.
Biologics used in rheumatology, dermatology, or gastroenterology have attracted psychiatric research interest because they can block specific inflammatory signals.
The most important lesson from this research is that patient selection may matter.
What the infliximab trial actually found
Infliximab is a TNF-alpha antagonist used for inflammatory diseases. Researchers tested it in a randomized proof-of-concept study involving treatment-resistant depression.
The randomized infliximab trial in treatment-resistant depression did not find that infliximab had generalized antidepressant efficacy across the full study population. However, exploratory analyses suggested greater benefit among patients with higher baseline inflammatory biomarkers.t conclusion from:
“TNF inhibitors treat depression.”
The trial's main lesson was more nuanced.
An immune-targeting intervention that fails in an unselected depression population might behave differently in a subgroup defined by inflammatory biology.
That hypothesis has helped drive interest in precision psychiatry.
It has not established TNF inhibitors as standard depression medications.
What the dupilumab research does and does not show
Dupilumab is being studied for mental health outcomes in people with atopic dermatitis, but current research should not be described as proof that an eczema drug is becoming an antidepressant.
Dupilumab blocks signaling involving IL-4 and IL-13 and is used for approved inflammatory conditions.
A current ClinicalTrials.gov study of dupilumab, anxiety, and depression symptoms is recruiting people with moderate-to-severe atopic dermatitis who are already receiving dupilumab. The study is examining changes in anxiety, depression symptoms, and related outcomes in that dermatology population. dy is atopic dermatitis.
This is not a randomized trial establishing dupilumab as a treatment for major depressive disorder.
Why might mood improve when an inflammatory skin condition improves?
Several explanations are possible:
Itching may decrease.
Sleep may improve.
Visible skin symptoms may improve.
Social distress may change.
Quality of life may improve.
Immune signaling itself may have a role.
A study has to separate those possibilities before researchers can claim a direct antidepressant effect.
So, the accurate headline is not:
“Eczema drug tested as a new antidepressant.”
A more accurate description is:
Researchers are studying mental health outcomes during immune-targeting treatment, including whether improvements are explained entirely by better physical health or may also reveal immune-mood connections.
Should people with depression get inflammation blood tests?
Not everyone with depression automatically needs CRP or cytokine testing solely to determine a psychiatric treatment plan.
A clinician may consider laboratory testing when the medical history, symptoms, medications, or broader clinical picture suggest a reason.
For example, a patient may need medical assessment because of:
Persistent fever or signs of illness
Unexplained weight changes
Significant fatigue
Possible autoimmune symptoms
Chronic inflammatory disease
Metabolic health concerns
Medication effects
Sleep disorder concerns
Other physical symptoms
A CRP test is nonspecific.
A high result can indicate inflammation without identifying the cause.
Similarly, a normal CRP result does not prove inflammation has no role in a person's depression biology.
Patients should be cautious about companies offering expensive “depression inflammation panels” that promise to identify the root cause of depression or select a guaranteed treatment.
A psychiatric evaluation and behavioral health assessment can help determine whether symptoms suggest the need for broader medical coordination.
Can anti-inflammatory drugs treat depression?
Anti-inflammatory medications and immune-targeting treatments remain an active area of depression research, but patients should not begin using them as depression treatments without appropriate medical care.
Some research has examined:
TNF inhibitors
Cytokine-targeting biologics
Minocycline
Certain anti-inflammatory medications
Metabolic and immune-related interventions
Results have varied.
One recurring research question is whether an anti-inflammatory strategy may appear ineffective when tested across all people with depression but show a signal in patients selected for higher inflammatory activity.
That hypothesis is promising.
It is not a prescription.
Common anti-inflammatory medications can have gastrointestinal, kidney, cardiovascular, bleeding, or other risks depending on the drug and patient.
Biologic medicines also have specific safety considerations and approved indications.
Do not start an anti-inflammatory medication, antibiotic, biologic, or supplement to treat depression based only on an inflammation theory.
A licensed clinician can help determine what is appropriate.
Decision-support table: When is the inflammation question worth discussing?
Use this table to prepare for a clinical conversation. It is not a diagnostic tool.
Your situation | Is inflammation worth discussing? | What to ask |
Depression has not improved enough after several treatments | Possibly | Should my diagnosis and medical history be reassessed? |
I have a diagnosed inflammatory or autoimmune condition | Yes | Could my medical and mental health care be coordinated? |
I have unexplained physical symptoms | Yes | Do these symptoms need a medical evaluation? |
My CRP was high on a previous test | Yes | What was the likely cause, and does it need follow-up? |
I saw a post saying high CRP means SSRIs will fail | Clarify the claim | What does current biomarker research actually establish? |
I want cytokine testing to choose an antidepressant | Discuss limitations | Is there a validated clinical reason for this test? |
I want to take an anti-inflammatory for depression | Discuss safety first | What risks and evidence apply to the specific medication? |
I take a biologic for another medical condition and my mood changed | Yes | Could symptom, sleep, disease, or treatment changes be relevant? |
I think I have “neuroinflammation” because I feel foggy | Broaden the evaluation | What other causes of cognitive symptoms should be considered? |
Troubleshooting: Common misconceptions about inflammatory depression
Inflammation research is easy to oversimplify. These corrections can help.
Claim you may hear | What is more accurate |
“Depression is caused by inflammation.” | Inflammation may contribute to depression in some people |
“High CRP proves inflammatory depression.” | CRP is nonspecific and does not diagnose a depression subtype |
“Inflammation means serotonin drugs cannot work.” | Treatment-response research is more complex |
“Brain fog proves neuroinflammation.” | Cognitive symptoms have many possible causes |
“Anti-inflammatory drugs are natural antidepressants.” | These drugs have risks and are not universal depression treatments |
“Biologics are the next depression cure.” | Immune-targeting depression research remains investigational |
“Dupilumab is being approved for depression.” | Current research I could verify examines mental health outcomes in atopic dermatitis populations |
“If my blood tests are normal, my depression is not biological.” | Depression biology cannot be reduced to one inflammation test |
A useful question for a clinician is:
“Is there anything in my medical history or symptom pattern that suggests we should look beyond depression treatment alone?”
That question leaves room for careful medical reasoning without assuming the answer.
How Sophroneo fits
Sophroneo Behavioral Health & TMS can help patients consider depression symptoms, previous treatment response, and advanced depression care within a broader behavioral health plan.
How Sophroneo may fit:
Psychiatric evaluations are available for children, adolescents, adults, and families.
Medication management and psychopharmacology are available when clinically appropriate.
Therapy options include CBT, culturally sensitive counseling, solution-focused therapy, motivational interviewing, family therapy, and group therapy.
NeuroStar TMS for major depression is available as a non-drug therapy when antidepressants have not helped enough.
Spravato esketamine therapy is available for treatment-resistant depression and is administered in clinic with safety monitoring.
Sophroneo participates in most major insurance plans and accepts private pay. Coverage can vary. Confirm benefits with Sophroneo or your insurance provider.
Sophroneo provides care in Powder Springs/Austell and Stone Mountain. The phone number is 770-999-9495.
Sophroneo should not be described as offering cytokine testing, CRP-guided antidepressant selection, or immune-targeting biologic treatment for depression unless Sophroneo confirms those specific services.
Assumptions and limitations
This article assumes the reader is researching inflammation and depression in the context of major depressive disorder or treatment-resistant depression. It does not diagnose an inflammatory subtype of depression.
Important limitations:
Higher inflammatory markers at the group level do not mean every person with depression has high inflammation.
Association does not establish that inflammation is the sole cause of depression.
CRP is a nonspecific inflammatory marker.
A blood CRP test does not directly measure neuroinflammation.
There is no single cytokine panel that diagnoses depression.
CRP-guided antidepressant selection remains a research area.
The infliximab trial did not show generalized antidepressant efficacy.
Dupilumab is not established or FDA-approved as a depression treatment.
Mood improvement during treatment of inflammatory disease may have several explanations.
Anti-inflammatory medications and biologics can have important risks.
Side effects, benefits, and treatment fit can vary.
A licensed clinician can help determine what is appropriate.
Frequently Asked Questions
What is the link between inflammation and depression?
Research has found that some inflammatory markers are higher on average in people with depression.
Scientists are studying whether immune signaling affects brain systems involved in mood, motivation, reward, energy, and stress. The relationship appears complex and may differ between patients.
Can inflammation cause depression?
Immune activation can affect mood and behavior, and some research supports a possible causal role in certain settings.
However, it is too broad to say that inflammation causes every case of depression. Depression may involve genetic, biological, psychological, social, medical, and environmental factors.
What is inflammatory depression?
Inflammatory depression is a research concept used to describe the possibility that some patients have a more inflammation-related biological profile.
It is not a diagnosis confirmed by one standard blood test.
What does CRP have to do with depression?
CRP is a blood marker associated with systemic inflammation.
Researchers have studied whether baseline CRP can predict antidepressant response or identify patients more likely to respond to particular treatments. These findings are promising but have not created a simple universal prescribing algorithm.
Should I ask for a CRP test if antidepressants are not working?
You can discuss your medical history and concerns with a clinician.
Whether CRP or other laboratory testing is appropriate depends on the broader clinical and medical picture. A CRP result alone does not diagnose treatment-resistant or inflammatory depression.
What is neuroinflammation?
Neuroinflammation refers broadly to immune-related activity involving the brain or central nervous system.
It is not the same as having a high CRP blood result. Research into microglia, cytokines, and central inflammatory activity is ongoing.
Is dupilumab being used to treat depression?
Dupilumab is not established as a depression treatment.
A current study is examining anxiety and depression symptoms in people with moderate-to-severe atopic dermatitis who are already receiving dupilumab. That is different from a clinical trial proving dupilumab treats major depressive disorder.
Do biologics work for depression?
Biologics are not routine depression treatments.
A proof-of-concept infliximab trial did not show generalized benefit across all participants with treatment-resistant depression, although exploratory findings suggested inflammatory biomarkers might identify a subgroup worth further study.
Can I take anti-inflammatory medication for depression?
Do not start medication to treat depression based only on an inflammation theory.
Anti-inflammatory drugs, antibiotics, and biologics have specific risks and medical uses. Depression treatment should be planned with an appropriate clinician.
If depression has not improved enough with previous treatment or physical health concerns are complicating the picture, consider scheduling an appointment to review symptoms, treatment history, medication management, therapy, TMS, Spravato, and whether broader medical coordination may be appropriate.